Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Integrated Community Oncology Network
• Collaborator: Sanofi
• Treatments: Oxaliplatin; Vinorelbine

Criteria

Inclusion Criteria:

• Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.

• Measurable disease

• Good performance status (ECOG 0,1 or 2)

Exclusion Criteria:

• Previously treated with Oxaliplatin or Navelbine

• Symptomatic CNS metastases